查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1691775

遺傳性血管性水腫治療市場 - 全球產業規模、佔有率、趨勢、機會和預測，按藥物類別、配銷通路、應用、地區和競爭細分，2020-2030 年預測

Hereditary Angioedema Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Distribution Channel, By Application, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球遺傳性血管性水腫治療市場價值為 43.6 億美元，預計到 2030 年將達到 72.8 億美元，複合年成長率為 8.89%。全球遺傳性血管性水腫治療市場正在經歷顯著擴張，這得益於人們認知的提高、診斷能力的提高以及新治療方案的推出。基因研究的進步使得早期和準確的診斷成為可能，從而可以及時干預和更好地管理疾病。製藥公司正專注於開發標靶療法，包括單株抗體和小分子抑制劑，以提供長期預防和急性治療解決方案。遺傳性血管性水腫盛行率的不斷上升，加上醫療支出的不斷增加和患者權益保護的不斷加強，進一步推動了市場的成長。此外，創新療法的監管批准以及皮下和口服治療方案的出現正在提高患者的依從性和便利性，為該行業創造了良好的前景。

市場概況
預測期 2026-2030
2024 年市場規模 43.6 億美元
2030 年市場規模 72.8 億美元
2025-2030 年複合年成長率 8.89％
成長最快的領域 預防
最大的市場 北美洲

強大的新藥通路和不斷增加的研發投入正在塑造競爭格​​局。生物製藥公司正在探索具有更高療效、更少副作用和改進給藥方法的下一代療法。從靜脈注射到皮下和口服治療的轉變正在改變護理標準，減輕患者和醫療保健提供者的負擔。製藥公司、研究機構和患者組織之間的合作和策略夥伴關係正在加速藥物開發和市場滲透。隨著越來越多的患者尋求預防措施而不是僅依賴急性治療，預防性治療的擴展預計將推動長期市場永續性。

主要市場促進因素

研發方面的進步

主要市場挑戰

治療費用高昂

主要市場趨勢

個人化醫療方法

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：全球遺傳性血管性水腫治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依藥物類別（C1 酯酶抑制劑、選擇性緩激肽 B2 受體拮抗劑、激肽釋放酶抑制劑、其他藥物類別）
    • 按配銷通路分類（醫院藥房、零售藥房、其他分銷管道）
    • 依用途（預防、按需）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖
    • 按藥物類別
    • 按配銷通路
    • 按應用
    • 按地區

第 5 章：亞太地區遺傳性血管性水腫治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按藥物類別
    • 按配銷通路
    • 按應用
    • 按國家
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第 6 章：歐洲遺傳性血管性水腫治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 7 章：北美遺傳性血管性水腫治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 墨西哥
    • 加拿大

第 8 章：南美洲遺傳性血管性水腫治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第 9 章：中東和非洲遺傳性血管性水腫治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 10 章：市場動態

  • 驅動程式
  • 挑戰

第 11 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 合併與收購

第 12 章：全球遺傳性血管性水腫治療市場：SWOT 分析

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • Shire plc
  • Sanofi SA
  • Pharming Healthcare Inc.
  • Attune Pharmaceuticals
  • Adverum Biotechnologies
  • Arrowhead Pharmaceuticals
  • Ionis Pharmaceuticals
  • BioCryst Pharmaceuticals Inc.
  • CSL Behring.
  • CENTOGENE NV

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 17501

Global Hereditary Angioedema Therapeutics Market was valued at USD 4.36 Billion in 2024 and is expected to reach USD 7.28 Billion in the forecast period with a CAGR of 8.89% through 2030. The global hereditary angioedema therapeutics market is experiencing significant expansion, driven by increasing awareness, improved diagnostic capabilities, and the introduction of novel treatment options. Advances in genetic research have enabled early and accurate diagnosis, allowing for timely intervention and better disease management. Pharmaceutical companies are focusing on developing targeted therapies, including monoclonal antibodies and small-molecule inhibitors, to provide long-term prophylaxis and acute treatment solutions. The growing prevalence of hereditary angioedema, coupled with rising healthcare expenditure and patient advocacy efforts, is further supporting market growth. Furthermore, regulatory approvals for innovative therapies and the emergence of subcutaneous and oral treatment options are enhancing patient adherence and convenience, creating a favorable outlook for the industry.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 4.36 Billion
Market Size 2030USD 7.28 Billion
CAGR 2025-20308.89%
Fastest Growing SegmentProphylaxis
Largest MarketNorth America

A strong pipeline of novel drugs and increased investment in research and development are shaping the competitive landscape. Biopharmaceutical companies are exploring next-generation therapies that offer enhanced efficacy, fewer side effects, and improved administration methods. The shift from intravenous to subcutaneous and oral treatments is transforming the standard of care, reducing the burden on patients and healthcare providers. Collaborations and strategic partnerships between pharmaceutical firms, research institutions, and patient organizations are accelerating drug development and market penetration. The expansion of prophylactic treatments is expected to drive long-term market sustainability, as more patients seek preventive measures rather than relying solely on acute treatments.

Key Market Drivers

Advancements in Research and Development (R&D)

Advancements in Research and Development (R&D) have been pivotal in boosting the Global Hereditary Angioedema Therapeutics Market. Hereditary Angioedema is a rare genetic disorder characterized by debilitating and unpredictable swelling episodes that can be life-threatening. In recent years, the relentless pursuit of scientific knowledge and innovative therapies has transformed the landscape of HAE treatment.

One of the most significant drivers of market growth has been the breakthrough discoveries in understanding the underlying mechanisms of HAE. Researchers have delved deep into the genetic and biochemical aspects of the disease, leading to a more precise understanding of how it develops and progresses. This increased knowledge has paved the way for the development of targeted therapies that are specifically designed to address the root causes of HAE.

Monoclonal antibodies, in particular, have emerged as a revolutionary approach in HAE therapeutics. These monoclonal antibodies, such as lanadelumab and ecallantide, have been engineered to specifically inhibit the activity of proteins like plasma kallikrein, which play a critical role in HAE attacks. This precision in drug design has proven highly effective in preventing and managing HAE episodes, providing patients with newfound hope and relief from the burden of their condition.

Key Market Challenges

High Treatment Costs

The High treatment costs have emerged as a significant obstacle hindering the growth and accessibility of the Global Hereditary Angioedema Therapeutics Market. HAE is a rare genetic disorder characterized by recurrent and potentially life-threatening swelling episodes. While advancements in therapeutics have improved the quality of life for HAE patients, the exorbitant cost of these treatments poses a considerable challenge. The prohibitively high cost of treatment makes these life-saving therapies inaccessible to a substantial portion of HAE patients, especially those without comprehensive health insurance coverage. This leads to disparities in access to care, with only a fraction of those in need benefiting from the latest advancements in HAE therapeutics.

For individuals who manage to access HAE therapies, the financial strain can be overwhelming. Copayments, deductibles, and out-of-pocket expenses can quickly accumulate, potentially forcing patients to make difficult choices between their healthcare needs and other essential expenses.

Access to HAE treatments is even more challenging in regions with limited healthcare resources and lower income levels. This exacerbates global healthcare disparities, where patients in wealthier nations have greater access to cutting-edge treatments, while those in less affluent regions struggle to secure even basic care.

Key Market Trends

Personalized Medicine Approaches

Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling in various body parts, including the extremities, face, gastrointestinal tract, and airway. This condition is caused by mutations in the SERPING1 gene, leading to deficient or dysfunctional C1 inhibitor (C1-INH) proteins, which play a crucial role in regulating inflammatory pathways.

Personalized medicine has significantly advanced the management of HAE by tailoring treatments to individual genetic profiles and disease manifestations. The process begins with precise genetic testing to identify specific mutations in the SERPING1 gene, which helps determine the subtype of HAE a patient has. This accurate diagnosis is essential, as it guides the selection of targeted therapies that address the underlying pathophysiological mechanisms.

For instance, patients with Type I HAE, characterized by low levels of functional C1-INH, may benefit from C1-INH replacement therapies such as Berinert or Cinryze. These treatments work by supplementing the deficient protein, thereby preventing or reducing the frequency of swelling episodes. Conversely, patients with normal C1-INH levels but dysfunctional protein (Type II HAE) might respond better to therapies that inhibit the kallikrein-kinin pathway, such as lanadelumab (Takhzyro), a monoclonal antibody that targets plasma kallikrein to prevent bradykinin formation, a key mediator of swelling in HAE.

Key Market Players

  • Shire plc
  • Sanofi SA
  • Pharming Healthcare Inc.
  • Attune Pharmaceuticals
  • Adverum Biotechnologies
  • Arrowhead Pharmaceuticals
  • Ionis Pharmaceuticals
  • BioCryst Pharmaceuticals Inc.
  • CSL Behring.
  • CENTOGENE N.V

Report Scope:

In this report, the Global Hereditary Angioedema Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hereditary Angioedema Therapeutics Market, By Drug Class:

  • C1 Esterase Inhibitor
  • Selective Bradykinin B2 Receptor Antagonist
  • Kallikrein Inhibitor
  • Other Drug Classes

Hereditary Angioedema Therapeutics Market, By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Other Distribution Channels

Hereditary Angioedema Therapeutics Market, By Application:

  • Prophylaxis
  • On-demand

Hereditary Angioedema Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hereditary Angioedema Therapeutics Market.

Available Customizations:

Global Hereditary Angioedema Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Hereditary Angioedema Therapeutics Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes)
    • 4.2.2. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels)
    • 4.2.3. By Application (Prophylaxis, On-demand)
    • 4.2.4. By Region
    • 4.2.5. By Company (2024)
  • 4.3. Market Map
    • 4.3.1. By Drug Class
    • 4.3.2. By Distribution Channel
    • 4.3.3. By Application
    • 4.3.4. By Region

5. Asia Pacific Hereditary Angioedema Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class
    • 5.2.2. By Distribution Channel
    • 5.2.3. By Application
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Hereditary Angioedema Therapeutics Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Drug Class
        • 5.3.1.2.2. By Distribution Channel
        • 5.3.1.2.3. By Application
    • 5.3.2. India Hereditary Angioedema Therapeutics Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Drug Class
        • 5.3.2.2.2. By Distribution Channel
        • 5.3.2.2.3. By Application
    • 5.3.3. Australia Hereditary Angioedema Therapeutics Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Drug Class
        • 5.3.3.2.2. By Distribution Channel
        • 5.3.3.2.3. By Application
    • 5.3.4. Japan Hereditary Angioedema Therapeutics Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Drug Class
        • 5.3.4.2.2. By Distribution Channel
        • 5.3.4.2.3. By Application
    • 5.3.5. South Korea Hereditary Angioedema Therapeutics Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Drug Class
        • 5.3.5.2.2. By Distribution Channel
        • 5.3.5.2.3. By Application

6. Europe Hereditary Angioedema Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Application
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Hereditary Angioedema Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Distribution Channel
        • 6.3.1.2.3. By Application
    • 6.3.2. Germany Hereditary Angioedema Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Distribution Channel
        • 6.3.2.2.3. By Application
    • 6.3.3. Spain Hereditary Angioedema Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Distribution Channel
        • 6.3.3.2.3. By Application
    • 6.3.4. Italy Hereditary Angioedema Therapeutics Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Drug Class
        • 6.3.4.2.2. By Distribution Channel
        • 6.3.4.2.3. By Application
    • 6.3.5. United Kingdom Hereditary Angioedema Therapeutics Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Drug Class
        • 6.3.5.2.2. By Distribution Channel
        • 6.3.5.2.3. By Application

7. North America Hereditary Angioedema Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Application
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Hereditary Angioedema Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Distribution Channel
        • 7.3.1.2.3. By Application
    • 7.3.2. Mexico Hereditary Angioedema Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Distribution Channel
        • 7.3.2.2.3. By Application
    • 7.3.3. Canada Hereditary Angioedema Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Distribution Channel
        • 7.3.3.2.3. By Application

8. South America Hereditary Angioedema Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Application
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Hereditary Angioedema Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Distribution Channel
        • 8.3.1.2.3. By Application
    • 8.3.2. Argentina Hereditary Angioedema Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Distribution Channel
        • 8.3.2.2.3. By Application
    • 8.3.3. Colombia Hereditary Angioedema Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Distribution Channel
        • 8.3.3.2.3. By Application

9. Middle East and Africa Hereditary Angioedema Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Application
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Hereditary Angioedema Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Distribution Channel
        • 9.3.1.2.3. By Application
    • 9.3.2. Saudi Arabia Hereditary Angioedema Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Distribution Channel
        • 9.3.2.2.3. By Application
    • 9.3.3. UAE Hereditary Angioedema Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Distribution Channel
        • 9.3.3.2.3. By Application

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Hereditary Angioedema Therapeutics Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Shire plc
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. Sanofi SA
  • 14.3. Pharming Healthcare Inc.
  • 14.4. Attune Pharmaceuticals
  • 14.5. Adverum Biotechnologies
  • 14.6. Arrowhead Pharmaceuticals
  • 14.7. Ionis Pharmaceuticals
  • 14.8. BioCryst Pharmaceuticals Inc.
  • 14.9. CSL Behring.
  • 14.10. CENTOGENE N.V.

15. Strategic Recommendations

16. About Us & Disclaimer